Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatorenal syndrome.

Sharon Turban1, Paul J Thuluvath, Mohamed G Atta

  • 1Division of Nephrology, Johns Hopkins University, 1830 East Monument Street, Suite 416, Baltimore, Maryland 21205, USA.

World Journal of Gastroenterology
|August 19, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rapid Reduction in Proteinuria With the Initiation of Voclosporin in Lupus Nephritis: A Single-Center Experience.

Cureus·2026
Same author

Association between interstitial fibrosis/tubular atrophy (IFTA) on kidney biopsies and anti Ro60 antibody positivity in patients with lupus nephritis (LN).

Lupus·2026
Same author

A Roadmap for Development of Community Engagement: Early Lessons Learned From the RECOVER Initiative.

Progress in community health partnerships : research, education, and action·2026
Same author

Budd-Chiari Syndrome: Presentation, Management, and Prognosis.

The American journal of gastroenterology·2025
Same author

Aggressive Recurrent Tumoral Calcinosis in a Patient With Kidney Failure.

Kidney medicine·2025
Same author

Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure.

Liver international : official journal of the International Association for the Study of the Liver·2025
Same journal

Lessons from extended induction and practical evidence for improving tofacitinib therapy in ulcerative colitis.

World journal of gastroenterology·2026
Same journal

Small animal <i>ex vivo</i> machine perfusion of the liver: A comprehensive literature review.

World journal of gastroenterology·2026
Same journal

Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics <i>vs</i> biosimilars.

World journal of gastroenterology·2026
Same journal

Diagnosis and management of metabolic dysfunction-associated steatohepatitis in patients with chronic hepatitis B infection.

World journal of gastroenterology·2026
Same journal

Simultaneous treatment of concomitant achalasia coexisting with epiphrenic diverticulum: The practice of submucosal tunneling technique.

World journal of gastroenterology·2026
Same journal

Lianhe Xiaozhi ointment ameliorates metabolic dysfunction-associated steatotic liver disease <i>via</i> peroxisome proliferator-activated receptor alpha pathway activation.

World journal of gastroenterology·2026
See all related articles

Hepatorenal syndrome (HRS) is reversible kidney failure in advanced liver disease. It stems from intense renal vasoconstriction due to altered hemodynamics, impacting kidney function.

Area of Science:

  • Nephrology
  • Hepatology
  • Internal Medicine

Background:

  • Hepatorenal syndrome (HRS) is a severe complication of advanced chronic liver disease.
  • It is characterized by functional renal failure with intense renal vasoconstriction.
  • Altered systemic and portal hemodynamics precipitate HRS.

Purpose of the Study:

  • To review the epidemiology of hepatorenal syndrome (HRS).
  • To elucidate the pathophysiology of HRS, focusing on renal hemodynamics.
  • To discuss current and emerging therapeutic strategies for HRS.

Main Methods:

  • Literature review of epidemiology, pathophysiology, and treatment of HRS.
  • Analysis of the interplay between liver disease and renal function.
  • Synthesis of current and novel therapeutic approaches.

Related Experiment Videos

Main Results:

  • HRS is a significant cause of mortality in patients with cirrhosis.
  • Renal vasoconstriction is driven by imbalances in vasoactive mediators.
  • Effective management requires addressing both liver dysfunction and renal impairment.

Conclusions:

  • Understanding HRS pathophysiology is crucial for effective treatment.
  • Emerging therapies offer new hope for patients with HRS.
  • Multidisciplinary management is key to improving outcomes in HRS.